UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 144

of 'Chemotherapy hepatotoxicity and dose modification in patients with liver disease'

144
TI
Mitomycin C and vinblastine chemotherapy for advanced breast cancer.
AU
Konits PH, Aisner J, van Echo DA, Lichtenfeld K, Wiernik PH
SO
Cancer. 1981;48(6):1295.
 
Mitomycin C, 20 mg/m2 day 1, and vinblastine, 0.15 mg/m2 days 1 and 21, were administered intravenously to 31 patients with refractory previously treated advanced breast cancer. Courses were repeated every six to eight weeks when adequate hematologic recovery permitted. Thirty of the 31 patients were evaluable; one had a complete response and 11 had a partial response. Four patients had stabilization of their disease. There was a 12/30 (40%) response rate with a median response duration of 127 days (range 69--412 days). Toxicity included moderate to severe myelosuppression, infections, hemorrhage, neurologic symptoms, pulmonary toxicity and mucositis. In previously treated patients with poor prognoses, the combination of mitomycin C and vinblastine appears to be a worthwhile secondary treatment for metastatic breast cancer.
AD
PMID